Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Fertig, Elana J ^a   Lee, Esak ^b   Pandey, Niranjan B ^b   Popel, Aleksander S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GLYCOPROTEIN GP 130; IL6ST PROTEIN, HUMAN; INTERLEUKIN 6; MESSENGER RNA; RANTES; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN C; VEGFA PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

BREAST TUMOR; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOKINE CCL5; CYTOKINE RECEPTOR GP130; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; RECEPTOR, ERBB-2; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84948715342     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12133     Document Type: Article

References (45)

1. DeSantis, C., Ma, J., Bryan, L. & Jemal, A. Breast cancer statistics, 2013. CA Cancer J Clin 64, 52-62 (2014).
2. Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767 (2011).
3. Eroles, P., Bosch, A., Bermejo, B. & Lluch, A. Mechanisms of resistance to hormonal treatment in breast cancer. Clin Transl Oncol 12, 246-252 (2010).
4. Lee, E. et al. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun 5, 4715 (2014).
5. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
6. Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13, 759-771 (2013).
7. Rot, A. & von Andrian, U. H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22, 891-928 (2004).
8. Athale, C. A. & Deisboeck, T. S. The effects of EGF-receptor density on multiscale tumor growth patterns. J Theor Biol 238, 771-779 (2006).
9. Li, T., Yang, J., Zhou, Q. & He, Y. Molecular regulation of lymphangiogenesis in development and tumor microenvironment. Cancer Microenviron 5, 249-260 (2012).
10. Cao, Y. et al. Forty-year journey of angiogenesis translational research. Sci Transl Med 3, 114rv113 (2011).
11. Chen, S. T. et al. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J Proteome Res 7, 1379-1387 (2008).
12. Lee, E., Pandey, N. B. & Popel, A. S. Lymphatic endothelial cells support tumor growth in breast cancer. Sci Rep 4, 5853 (2014).
13. Stacker, S. A. et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14, 159-172 (2014).
14. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
15. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
16. Dethlefsen, C., Hojfeldt, G. & Hojman, P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138, 657-664 (2013).
17. Iliopoulos, D., Hirsch, H. A., Wang, G. & Struhl, K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 108, 1397-1402 (2011).
18. De Luca, A., Lamura, L., Gallo, M., Maffia, V. & Normanno, N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem 113, 3363-3370 (2012).
19. Yi, E. H. et al. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 11, 31-42 (2013).
20. Roberti, M. P. et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther 13, 1123-1140 (2012).
21. Wang, S. W. & Sun, Y. M. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol 44, 1032-1040 (2014).
22. Tell, R. W. & Horvath, C. M. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors. Proc Natl Acad Sci U S A 111, 12787-12792 (2014).
23. Ara, T. et al. Critical Role of STAT3 in IL-6-Mediated Drug Resistance in Human Neuroblastoma. Cancer Res 73, 3852-3864 (2013).
24. Ashizawa, T. et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8, 124-131 (2005).
25. Xiong, H. et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelialmesenchymal transition. J Biol Chem 287, 5819-5832 (2012).
26. Lee, H. et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 16, 1421-1428 (2010).
27. Taga, T. IL6 signalling through IL6 receptor and receptor-associated signal transducer, gp130. Res Immunol 143, 737-739 (1992).
28. Shah, N. et al. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERalpha and inducing IL-6 expression. Cancer Res 73, 5449-5458 (2013).
29. Hicks, D. G. et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30, 1097-1104 (2006).
30. Azim, H. A. & Azim, H. A., Jr. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncol 8, 135-144 (2012).
31. Campone, M., Frenel, J. S., Andre, F., Bachelot, T. & Juin, P. [Tumor resistance to HER2 inhibitors: the drug sedimentation concept]. Bull Cancer 99, 665-672 (2012).
32. Alameddine, R. S., Otrock, Z. K., Awada, A. & Shamseddine, A. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol 25, 313-324 (2013).
33. Vamesu, S. Angiogenesis and co-expressed of ER and c-erbB-2 (HER2/neu) protein in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom J Morphol Embryol 49, 469-478 (2008).
34. de Candia, P. et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci U S A 100, 12337-12342 (2003).
35. Bender, R. J. & Mac Gabhann, F. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One 8, e61788 (2013).
36. Sakurai, A., Doci, C. L. & Gutkind, J. S. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. Cell Res 22, 23-32 (2012).
37. Schoppmann, S. F. et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol 21, 955-960 (2010).
38. Emens, L. A. GM-CSF-secreting vaccines for solid tumors. Curr Opin Investig Drugs 10, 1315-1324 (2009).
39. Emens, L. A. et al. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 15, 313-337 (2004).
40. Eubank, T. D. et al. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res 69, 2133-2140 (2009).
41. Park, B. K. et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GMCSF. Nat Med 13, 62-69 (2007).
42. Wan, S. et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147, 1393-1404 (2014).
43. Xu, H. et al. Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer 14, 330 (2014).
44. Sung, S. Y. et al. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One 8, e71637 (2013).
45. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1 (2013).